Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) EBITDA Margin: 2020-2021

Historic EBITDA Margin for Cardiol Therapeutics (CRDL) over the last 2 years, with Dec 2021 value amounting to -40,170.45%.

  • Cardiol Therapeutics' EBITDA Margin fell 3720.00% to 60.30% in Q3 2022 from the same period last year, while for Sep 2022 it was 20.32%, marking a year-over-year change of. This contributed to the annual value of -40,170.45% for FY2021, which is 4027021.00% down from last year.
  • As of FY2021, Cardiol Therapeutics' EBITDA Margin stood at -40,170.45%, which was down 40,366.83% from 99.76% recorded in FY2020.
  • Over the past 5 years, Cardiol Therapeutics' EBITDA Margin peaked at 99.76% during FY2020, and registered a low of -40,170.45% during FY2021.
  • In the last 2 years, Cardiol Therapeutics' EBITDA Margin had a median value of -20,035.34% in 2020 and averaged -20,035.34%.
  • Data for Cardiol Therapeutics' EBITDA Margin shows a maximum YoY plummeted of 4,027,021bps (in 2021) over the last 5 years.
  • Yearly analysis of 2 years shows Cardiol Therapeutics' EBITDA Margin stood at 99.76% in 2020, then tumbled by 4,027,021bps to -40,170.45% in 2021.